- Home
- AWP vs EDIT Comparison
AWP vs EDIT Comparison
Compare AWP & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AWP
- EDIT
- Stock Information
- Founded
- AWP 2007
- EDIT 2013
- Country
- AWP United States
- EDIT United States
- Employees
- AWP N/A
- EDIT N/A
- Industry
- AWP Trusts Except Educational Religious and Charitable
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AWP Finance
- EDIT Health Care
- Exchange
- AWP Nasdaq
- EDIT Nasdaq
- Market Cap
- AWP 368.1M
- EDIT 327.0M
- IPO Year
- AWP N/A
- EDIT 2016
- Fundamental
- Price
- AWP $4.31
- EDIT $2.41
- Analyst Decision
- AWP
- EDIT Buy
- Analyst Count
- AWP 0
- EDIT 13
- Target Price
- AWP N/A
- EDIT $9.38
- AVG Volume (30 Days)
- AWP 331.5K
- EDIT 2.0M
- Earning Date
- AWP 01-01-0001
- EDIT 11-04-2024
- Dividend Yield
- AWP 12.48%
- EDIT N/A
- EPS Growth
- AWP N/A
- EDIT N/A
- EPS
- AWP N/A
- EDIT N/A
- Revenue
- AWP N/A
- EDIT $61,759,000.00
- Revenue This Year
- AWP N/A
- EDIT N/A
- Revenue Next Year
- AWP N/A
- EDIT N/A
- P/E Ratio
- AWP N/A
- EDIT N/A
- Revenue Growth
- AWP N/A
- EDIT 150.95
- 52 Week Low
- AWP $3.06
- EDIT $2.35
- 52 Week High
- AWP $4.20
- EDIT $11.69
- Technical
- Relative Strength Index (RSI)
- AWP 50.55
- EDIT 46.33
- Support Level
- AWP $4.18
- EDIT N/A
- Resistance Level
- AWP $4.38
- EDIT $3.38
- Average True Range (ATR)
- AWP 0.10
- EDIT 0.21
- MACD
- AWP 0.01
- EDIT -0.15
- Stochastic Oscillator
- AWP 69.57
- EDIT 70.88
About AWP abrdn Global Premier Properties Fund of Beneficial Interest
Aberdeen Global Premier Properties Fund is a diversified, closed-end management investment company. Its objective is to seek high current income and capital appreciation. It predominantly invests in equity and debt securities of domestic and foreign issuers which are principally engaged in the real estate industry, real estate financing or control real estate assets. Its portfolio of investments consists securities of Industrial REITs, Retail REITs, Data Center REITs, Health Care REITs and others.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.